Compare NWL & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWL | GENB |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1995 | N/A |
| Metric | NWL | GENB |
|---|---|---|
| Price | $5.79 | $17.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $4.97 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 15.3M | 1.1M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,742,200,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.58 | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.14 | N/A |
| 52 Week Low | $3.07 | $11.00 |
| 52 Week High | $6.64 | $18.18 |
| Indicator | NWL | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 70.20 | 66.93 |
| Support Level | $3.32 | $11.73 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.35 | 1.22 |
| MACD | 0.09 | 0.29 |
| Stochastic Oscillator | 77.12 | 87.19 |
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.